After eight years of clinical trials and tests, in September 2000, mifepristone (RU 486) was finally approved by the Food and Drug Administration for use as a non-surgical early abortion option.  The drug represents a significant step forward for American women's reproductive health.  However, having failed to block FDA approval of this proven safe and effective drug, anti-choice lawmakers have mounted a multi-front legislative campaign against it. 

One such proposal, S.3939, introduced by anti-choice Sen. David Vitter in the 109th Congress, would impose a number of onerous and unnecessary restrictions on the drug’s availability – making it virtually impossible for any provider to meet all its requirements.  Furthermore, the bill is designed to scare women seeking early abortion care by requiring doctors to give their patients misleading information regarding the drug’s safety record.

Click here to download a printable PDF of the entire document.